Aaron S Mansfield1, James T Symanowski2, Tobias Peikert3. 1. Department of Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, MN, United States. Electronic address: mansfield.aaron@mayo.edu. 2. Department of Cancer Biostatistics, Levine Cancer Institute Carolinas HealthCare System, Charlotte, NC, United States. 3. Department of Internal Medicine, Division of Pulmonary Medicine, Mayo Clinic, Rochester, MN, United States.
Abstract
RATIONALE: Malignant pleural mesothelioma is an almost universally fatal malignancy primarily related to asbestos exposure. Based on the differences in immunologic markers and gene expression between histologic subtypes of mesothelioma, and our clinical impression that response rates vary by histology, we decided to examine the reported response rates of mesothelioma subtypes. OBJECTIVES: Our objective was to compare the response rates of sarcomatoid mesotheliomas to the overall response rates in published clinical trials. METHODS: We searched PubMed for "mesothelioma" with the clinical trials filter selected. We included articles published between January 1, 2000 and March 20, 2014 in which subjects received first or second line systemic therapy for malignant pleural mesothelioma. Studies investigating multi-modality therapy including surgery were excluded. Response rates [including 95% confidence intervals (95% CI)] were estimated for the entire patient cohort and then separately for subjects with sarcomatoid tumors. MEASUREMENTS AND MAIN RESULTS: We reviewed 544 publications of which 41 trials met our inclusion criteria. Eleven of these trials did not include patients with sarcomatoid mesothelioma (27% of eligible studies). The remaining 30 publications included 1475 subjects, 1011 with epithelioid tumors (68.5%), 203 with biphasic tumors (13.8%), 137 with sarcomatoid tumors (9.3%) and 124 with unknown subtypes (8.4%). In total, there were 323 responses (21.9%, complete and partial responses, 95% CI: 16.3, 28.8) to systemic therapy across all histological subtypes. In patients with sarcomatoid tumors (n=137) 19 responses were observed. This accounted for 5.9% of all responses and yields a 13.9% (95% CI: 8.6, 21.6) response rate for patients with sarcomatoid tumors. Multiple biases likely affected this systematic review. CONCLUSION: Response rates for different histological subtypes of malignant pleural mesothelioma are infrequently reported. Partial and complete responses to systemic therapies appear to be less common among patients with sarcomatoid tumors.
RATIONALE: Malignant pleural mesothelioma is an almost universally fatal malignancy primarily related to asbestos exposure. Based on the differences in immunologic markers and gene expression between histologic subtypes of mesothelioma, and our clinical impression that response rates vary by histology, we decided to examine the reported response rates of mesothelioma subtypes. OBJECTIVES: Our objective was to compare the response rates of sarcomatoid mesotheliomas to the overall response rates in published clinical trials. METHODS: We searched PubMed for "mesothelioma" with the clinical trials filter selected. We included articles published between January 1, 2000 and March 20, 2014 in which subjects received first or second line systemic therapy for malignant pleural mesothelioma. Studies investigating multi-modality therapy including surgery were excluded. Response rates [including 95% confidence intervals (95% CI)] were estimated for the entire patient cohort and then separately for subjects with sarcomatoid tumors. MEASUREMENTS AND MAIN RESULTS: We reviewed 544 publications of which 41 trials met our inclusion criteria. Eleven of these trials did not include patients with sarcomatoid mesothelioma (27% of eligible studies). The remaining 30 publications included 1475 subjects, 1011 with epithelioid tumors (68.5%), 203 with biphasic tumors (13.8%), 137 with sarcomatoid tumors (9.3%) and 124 with unknown subtypes (8.4%). In total, there were 323 responses (21.9%, complete and partial responses, 95% CI: 16.3, 28.8) to systemic therapy across all histological subtypes. In patients with sarcomatoid tumors (n=137) 19 responses were observed. This accounted for 5.9% of all responses and yields a 13.9% (95% CI: 8.6, 21.6) response rate for patients with sarcomatoid tumors. Multiple biases likely affected this systematic review. CONCLUSION: Response rates for different histological subtypes of malignant pleural mesothelioma are infrequently reported. Partial and complete responses to systemic therapies appear to be less common among patients with sarcomatoid tumors.
Authors: Y Oh; R Perez-Soler; F V Fossella; B S Glisson; J Kurie; G L Walsh; M Truong; D M Shin Journal: Invest New Drugs Date: 2000-08 Impact factor: 3.850
Authors: Aaron Scott Mansfield; Anja C Roden; Tobias Peikert; Yuri M Sheinin; Susan M Harrington; Christopher J Krco; Haidong Dong; Eugene D Kwon Journal: J Thorac Oncol Date: 2014-07 Impact factor: 15.609
Authors: H S Parra; L Tixi; F Latteri; S Bretti; M Alloisio; A Gravina; R Lionetto; P Bruzzi; C Dani; R Rosso; M Cosso; L Balzarini; A Santoro; A Ardizzoni Journal: Cancer Date: 2001-08-01 Impact factor: 6.860
Authors: A K Nowak; M J Byrne; R Williamson; G Ryan; A Segal; D Fielding; P Mitchell; A W Musk; B W S Robinson Journal: Br J Cancer Date: 2002-08-27 Impact factor: 7.640
Authors: Simone B S P Terra; Aaron S Mansfield; Haidong Dong; Tobias Peikert; Anja C Roden Journal: Oncoimmunology Date: 2017-07-27 Impact factor: 8.110
Authors: Sara V Soldera; John Kavanagh; Melania Pintilie; Natasha B Leighl; Marc de Perrot; John Cho; Andrew Hope; Ronald Feld; Penelope A Bradbury Journal: Oncologist Date: 2018-11-26